This is the authors' abstract. We don't add key points for this paper.
Background: Palmar-plantar atopic dermatitis is a common and debilitating condition with significant diagnostic and management challenges. Case Presentation: The paper presents the successful treatment of dupilumab in five female patients with recalcitrant palmar-plantar atopic dermatitis. Methods: The Hand Eczema Severity Index (HECSI) and the Foot Eczema Severity Index (FECSI), eosinophils and IgE levels were evaluated before and after the treatment. Results: Five recalcitrant palmar-plantar atopic dermatitis patients had substantial responses to dupilumab and the persistent pruritus was soon alleviated during the therapy. By week 16, all patients' palmar-plantar eczema has been almost clear, with significant decrease of HECSI and FECSI. The count of eosinophils and IgE levels returned to normal in all patients. Conclusion: Dupilumab significantly improves disease severity and reduces eosinophils and IgE in refractory palmar-plantar AD patients.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: